TECH:NGS-Bio-Techne Corp (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 83.5

Change

-0.65 (-0.77)%

Market Cap

USD 3.93B

Volume

1.15M

Analyst Target

USD 291.13
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Bio-Techne Corp and its subsidiaries develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. The Company's business segments are the Biotechnology, Clinical Controls and Protein Platforms divisions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+12.29 (+2.77%)

USD 117.92B
REGN Regeneron Pharmaceuticals Inc

+10.25 (+1.06%)

USD 108.54B
MRNA Moderna Inc

-8.94 (-5.90%)

USD 63.85B
ARGX argenx NV ADR

+8.86 (+2.45%)

USD 22.97B
BNTX BioNTech SE

+1.85 (+1.87%)

USD 22.68B
ALNY Alnylam Pharmaceuticals Inc

-1.60 (-1.07%)

USD 18.98B
GMAB Genmab AS

+0.21 (+0.75%)

USD 18.15B
BGNE BeiGene Ltd

-5.40 (-3.50%)

USD 17.32B
RPRX Royalty Pharma Plc

+1.02 (+3.87%)

USD 15.90B
BMRN Biomarin Pharmaceutical Inc

+0.59 (+0.79%)

USD 14.34B

ETFs Containing TECH

PBE Invesco Dynamic Biotechno.. 5.80 % 0.57 %

+0.54 (+1.75%)

USD 0.26B
GNOG:LSE Global X Genomics & Biote.. 4.77 % 0.00 %

+0.09 (+1.75%)

USD 6.80M
GN0M:XETRA Global X Genomics & Biote.. 3.76 % 0.00 %

+0.08 (+1.75%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.76 % 0.00 %

+0.11 (+1.75%)

USD 6.77M
RNMC First Trust Mid Cap US Eq.. 1.22 % 0.60 %

+0.42 (+1.75%)

USD 0.02B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

+0.36 (+1.75%)

USD 0.33B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.06 (1.75%)

USD 0.10B
IS3V:XETRA iShares Global Inflation .. 0.00 % 0.00 %

+0.03 (+1.75%)

USD 0.20B
OUFH:XETRA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.22% 62% D 70% C-
Dividend Return 0.21% 17% F 10% F
Total Return 8.42% 62% D 69% C-
Trailing 12 Months  
Capital Gain 1.78% 65% D 50% F
Dividend Return 0.39% 17% F 3% F
Total Return 2.17% 65% D 47% F
Trailing 5 Years  
Capital Gain 2,606.37% 99% N/A 99% N/A
Dividend Return 20.91% 50% F 82% B
Total Return 2,627.28% 99% N/A 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 321.77% 97% N/A 99% N/A
Dividend Return 323.12% 97% N/A 99% N/A
Total Return 1.34% 17% F 33% F
Risk Return Profile  
Volatility (Standard Deviation) 523.42% 10% F 2% F
Risk Adjusted Return 61.73% 97% N/A 84% B
Market Capitalization 3.93B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 39.90 13% 15%
Price/Book Ratio 5.34 27% 21%
Price / Cash Flow Ratio 52.13 2% 5%
Price/Free Cash Flow Ratio 29.02 2% 8%
Management Effectiveness  
Return on Equity 10.40% 96% 78%
Return on Invested Capital 11.50% 88% 80%
Return on Assets 6.11% 97% 89%
Debt to Equity Ratio 17.80% 48% 62%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.